Cardiff Oncology, Inc. (NASDAQ: CRDF) announced it will present preclinical data on its PLK1 inhibitor onvansertib at the American Association ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE